What To Look Out For At ESMO 2024

Attendees at this year's European Society for Medical Oncology meeting in Barcelona can look forward to a range of interesting datasets, from Phase III trials of established products in new settings to preliminary studies of novel products coming through the pipeline.  

Sagrada Familia, Barcelona
Barcelona Is The Venue For ESMO 2024 • Source: Shutterstock

Among the presentations at the European Society for Medical Oncology meeting in Barcelona, Spain will be data for older immune checkpoint inhibitors from Merck & Co., Inc., AstraZeneca PLC and Bristol Myers Squibb Company in earlier lines of treatment, plus new results from the troubled TIGIT class. An array of early-stage results for innovative anticancers including drugs targeting claudin-6 and CDK2, and protein degraders will also be on show, at the conference which will run from 13-17 September.

More from Clinical Trials

More from R&D